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Focal adhesion kinase (FAK), a non-receptor tyro-
sine kinase, mediates integrin-based cell signaling by
transferring signals regulating cell migration, adhe-
sion, and survival from the extracellular matrix to the
cytoplasm. Following autophosphorylation at tyrosine
397, FAK binds the Src homology 2 domains of Src and
phosphoinositide 3-kinase, among several other possi-
ble binding partners. To further investigate the role of
phosphorylated FAK in cell migration in situ, peptides
comprising residues 391–406 of human FAK with caged
phosphotyrosine 397 were synthesized. Although the
caged phosphopeptides were stable to phosphatase ac-
tivity, the free phosphopeptides showed a half-life of
10–15 min in cell lysates. Migrating NBT-II cells (a rat
bladder tumor cell line) were microinjected with the
caged FAK peptide and locally photoactivated using a
focused laser beam. The photoactivation of caged FAK
peptide in 8-m diameter spots over the cell body led
to the temporary arrest of the leading edge migration
within 1 min of irradiation. In contrast, cell body
migration was not inhibited. Microinjection of a non-
caged phosphorylated tyrosine 397 FAK peptide into
migrating NBT-II cells also led to lamellar arrest; how-
ever, this approach lacks the temporal control af-
forded by the caged phosphopeptides. Photoactivation
of related phosphotyrosine peptides with altered se-
quences did not result in transient lamellar arrest. We
hypothesize that the phosphorylated FAK peptide
competes with the endogenous FAK for binding to FAK
effectors including, but not limited to, Src and phos-
phoinositide 3-kinase, causing spatiotemporal mis-
regulation and subsequent lamellar arrest.
Focal adhesions are cell-surface specializations that connect
the extracellular matrix to the actin cytoskeleton. Transmem-
brane integrins and associated cytoskeletal proteins, including
talin, vinculin, -actinin, and filamin, perform this function
within the focal adhesion (1, 2). In addition, focal adhesions
contain numerous regulatory molecules, including focal adhe-
sion kinase (FAK),1 which is a non-receptor tyrosine kinase.
Cell binding to the extracellular matrix clusters integrins,
which, in turn, stimulates phosphorylation of FAK on tyrosine
397; this creates docking sites where SH2 domain-containing
proteins, such as Src, can bind. In this way, FAK links integrin
receptors to intracellular signaling events related to cell migra-
tion and survival.
The importance of FAK in cell migration was demonstrated
when FAK null fibroblasts showed reduced migration com-
pared with wild type cells generated from the same stage of
mouse embryos (3). The migration defect could be rescued by
expression of wild type FAK (4, 5). Overexpression of FAK in
Chinese hamster ovary cells also resulted in increased migra-
tion (6). However, neither re-expression of mutated FAK
(Y397F) in the FAK null cells nor overexpression of Y397F in
Chinese hamster ovary cells enhanced migration. Upon phos-
phorylation, the region containing tyrosine 397 may bind to the
SH2 domains of Src (7, 8), phospholipase C-1 (9, 10), phos-
phatidylinositol 3-kinase (PI3K) (10, 11), Grb7 (12–14), Nck-2
(15), and Shc (16), thus mediating numerous downstream ef-
fects. The defect in the stimulation of migration exhibited by
Y397F is presumably because of a resultant inability to recruit
one or more of these binding partners.
FAK phosphopeptides have been synthesized to test interac-
tions of phosphotyrosine 397 (pTyr397 FAK) with the SH2 do-
mains of Src (17) and PI3K, respectively (11). Chen (11) used a
FAK Tyr397 phosphopeptide to disrupt the binding of the p85
subunit of PI3K to full-length FAK in vitro using GST fusion
proteins. Peptides containing the pTyr397 FAK region of FAK
might therefore be useful for probing FAK function in migrat-
ing cells. In the present work, we investigated the role of
pTyr397 FAK within FAK by introducing photoactivatable
caged phosphopeptides containing Tyr397 and the surrounding
sequence into migrating cells.
A caged compound includes a photocleavable protecting
group that masks an essential functionality. In this context, a
peptide or protein is prepared by covalently linking a photo-
labile protecting group to a limited number of critical func-
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tional groups in the biomolecule (18). The caged peptides can be
introduced into the cells by microinjection. Upon removal of the
caging moiety by photolysis, the bioactive form of the peptide or
protein is produced within the cell (19, 20). Photoactivation of
caged proteins/peptides thus offers insights into cellular dy-
namics not achievable using genetic methods: perturbations
that can be controlled temporally and, in some cases, spatially
are followed with subsequent observations of altered cell be-
havior. However, thus far, there are few studies using caged
peptides and proteins to study cell migration (21–24).
In this study, we showed that photoactivation of a caged
phosphotyrosine peptide (cpTyr397FAK), based on the sequence
of FAK from residues Val391 to Thr406 surrounding the auto-
phosphorylation site at Tyr397, alters cell migration by tempo-
rarily halting lamellar extension. The effect on migration is
specific for the pTyr397FAK sequence because similar peptides
containing phosphotyrosine but with altered surrounding res-
idues fail to alter cell migration upon uncaging. The time scale
of temporary inhibition of migration is consistent with the time
to dephosphorylate the pTyr397FAK peptide in cell lysates. We
speculate that the phenotype is related to perturbation of FAK-




Peptides containing tyrosine (Tyr), free phosphotyrosine (pTyr), and
caged phosphotyrosine (cpTyr) were synthesized using standard Fmoc
solid phase peptide synthesis protocols, purified by high performance
liquid chromatography (HPLC), and confirmed as the desired products
by mass spectrometry. The caged phosphotyrosine residue was incor-
porated into the peptide sequence using a new building block for solid
phase synthesis (25). All peptide synthesis reagents were purchased
from Applied Biosystems or Novabiochem, and all other chemicals were
purchased from Sigma or Molecular Probes. High performance liquid
chromatography was performed using a Waters 600E HPLC fitted with
a Waters 600 automated control module and a Waters 2487 dual wave-
length absorbance detector recording at 228 and 280 nm. For analytical
HPLC a Beckman Ultrasphere C18, 5 m, 4.6  150-mm reverse phase
column was used. For preparative separations a YMC-pack, C18, 250 
20-mm reverse phase column was used. The standard gradient for
analytical and preparatory HPLC used was 93:7–0:100 over 35 min
(water:acetonitrile, 0.1% trifluoroacetic acid). Electrospray ionization
mass spectrometry was performed on a PerSeptive Biosystems Mariner
Biospectrometry Workstation (turbo ion source).
Peptide Synthesis—Peptide synthesis was made using standard solid
phase peptide synthesis protocols on a 0.05-mmol scale using a 0.21
mmol/g loading PAL-PEG-PS solid support. Amino acids were pur-
chased from Novabiochem as protected Fmoc amino acids with the
standard side chain protecting scheme: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-
OH, Fmoc-Asp(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ile-OH, Fmoc-
Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)-OH, and Fmoc-Val-
OH. Phosphotyrosine was introduced as the monobenzyl ester
Fmoc-Tyr(PO(OBzl)OH)-OH.
Amino acids were manually coupled in 4-fold excess using a mixture
of O-benzotriazolyl-N-N-N-N-tetramethyluronium hexafluorophos-
phate (HBTU) and 1-hydroxybenzotriazole (HOBt) and N,N-diisopro-
pylethylamine (DIEA) in DMF as activating agents. Each amino acid
was activated for 2 min with the HBTU/HOBt mixture and DIEA in
DMF before being added to the resin. Amide coupling reactions were
conducted for 1 h and monitored using the 2,4,6-trinitrobenzenesul-
phonic acid TNBS test (26). Deprotection of the base-labile Fmoc pro-
tecting group was accomplished by treating the resin with 20% piperi-
dine in DMF solution for 15 min. Acetylation was accomplished by
treating the resin with acetic anhydride and DIEA in DMF. Peptides
were cleaved from the resin, and side chain protecting groups were
simultaneously removed by treatment with the following cleavage mix-
ture: 50 l of dichloromethane, 25 l of triisopropyl silane, 25 l of
water, and 950 l of trifluoroacetic acid (1 ml of mixture/50 mg of resin)
for 2 h at room temperature. All peptides were precipitated with diethyl
ether (4 °C) and further purified by HPLC. Operations involving the
caged phosphotyrosine peptides were performed in the dark.
Detailed Protocol for a Typical Coupling—Piperidine (3 ml, 20% in
DMF) was added to 0.05 mmol FmocHN-AEIIDEEDT in solid support,
and nitrogen was passed through the mixture for 15 min. The resin was
then filtered and washed with DMF (3  3 ml  3 min), and the TNBS
test was run with a small resin sample to confirm that the deprotection
was successful. In a separate vessel, Fmoc-Tyr(tBu)-OH (79 mg, 0.2
mmol) was dissolved in HOBt/HBTU solution (1 ml 0.2 M HBTU, 0.2 M
HOBt in DMF), and DIEA (1.5 ml of 0.195 M solution in DMF) was
added. The resulting mixture was activated for 2 min and then added to
the resin. Nitrogen was passed through the resin suspension for 1 h, at
which time the TNBS test of a small resin sample was negative. The
resin was washed with DMF (3  3 ml  3 min) and subjected to the
subsequent deprotection/coupling cycles in a similar manner.
Acetylation—A 500-l aliquot of acetic anhydride and DIEA (3 ml,
0.195 M in DMF) were added to the resin-bound free amino-terminal
peptide. Nitrogen was passed through the mixture for 15 min. The resin
was filtered and washed with DMF (3  3 ml  3 min) and CH2Cl2 (2 
3 ml  3 min) and dried under vacuum before cleavage.
Cleavage—A 0.05-mmol sample of resin-bound peptide was dried
overnight and placed in a 50-ml flask. To this, 5 ml of the cleavage
mixture (250 l of CH2Cl2, 125 l of water, 125 l of tri-isopropylsilane,
trifluoroacetic acid to 5 ml) was added, and the resulting mixture was
shaken for 2 h, the resin was filtered, and the trifluoroacetic acid
filtrate was concentrated under an argon stream to a volume of 2 ml and
added over ice-cold ethyl ether (40 ml). After 5 min, the peptide was
centrifuged and washed again with 40 ml of cold ether. The solid
residue was dried under argon, redissolved in acetonitrile/water 1:1 (5
ml), and purified by preparative reverse phase HPLC. The pooled frac-
tions were lyophilized and redissolved in deionized water. In some
cases, addition of a small amount of base (0.05% NaHCO3) was neces-
sary to solubilize the peptides. The identity of the final peptide products
was confirmed by electrospray ionization mass spectrometry.
Coupling with Rhodamine—For rhodamine coupling, a 0.015-mmol
aliquot of free amine-containing peptide on solid support was washed
with DMF (3  3 ml  3 min) and filtered. The resin was then
suspended in DMF (500 l) and DIEA (50 l, 0.3 mmol, 20 eq), and to
this mixture was added 5 (and 6)-carboxy)-X-rhodamine, succinimidyl
ester (12 mg, 0.02 mmol). The resulting mixture was stirred in the dark
overnight. The resin was filtered, washed with DMF (3  3 ml  3 min),
iPrOH (2  3 ml  3 min), and dichloromethane (3  3 ml  3 min),
dried under vacuum, and stored at 4 °C.
Peptide Characterization—Peptides were purified by reverse phase
HPLC, and concentrations of stock solutions were determined by quanti-
tative amino acid analysis. When bright chromophores were present (rho-
damine), then the reported extinction coefficients for those chromophores
were used for calculating the concentrations by spectrophotometry.
cpTyr397FAK sequence: Ac-VSETDD-cpY-AEIIDEEDT-CONH2,
C86H125N18O42P, Mass.: 2112.8, MS(ESI); 1057.9 ([MH2]
2 (100); 720.3,
[MHNa2]
3 (8)),  (M1, cm1) 5332 (267 nm).
pTyr397FAK sequence: Ac-VSETDD-pY-AEIIDEEDT-CONH2,
C78H118N17O40P, Mass.: 1963.7, MS(ESI); 1057.9, [MH2]
2 (100).  (M1,
cm1) 350 (264 nm).
Rh-Ahx-cpTyr397FAK sequence: Rh-Ahx-VSETDD-cpY-AEI-
IDEEDT-CONH2, C123H163N21O46P
, Mass.: 2701.1, MS(ESI): 908.3
[MHNa]3 (70), 915.6 [MNa2]
3 (100), 923 [MNa3-H]




, Mass.: 2552.0, MS(ESI): 866.0 [MNa2]
3
(60), 873.6 [MNa3-H]
3, (100) 880.6 [MNa4-2H]




, Mass.: 2472.0, MS(ESI): 1248.0 [Mna]2
(100), 1259.0 [MNa2-H]
2, (40) 1270.0 [MNa3-2H]
2 (25);  (M1, cm1)
80,000 (576 nm).
Ala395cpTyr397FAK sequence: Ac-VSETAD-cpY-AEIIDEEDT-
CONH2, C85H125N18O40P, Mass.: 2068.8, characterized before final
acetylation: C83H123N18O39P, Mass.: 2026.8 MS(ESI); 1014.8 [MH2]
2
(100), 1025.8 [MHNa]2 (20);  (M1, cm1) 5332 (267 nm).
Ala395pTyr397FAK sequence: Ac-VSETAD-pY-AEIIDEEDT-CONH2,
C77H118N17O38P, Mass.: 1919.7, MS(ESI): 982.8 [MNa2]
2 (70), 993.8
[MNa3-H]
2 (100), 1004.8 [MNa4-2H]
2 (60), 1015.7 [MNa5-3H]
2 (30).
Ala395Ala396cpTyr397FAK sequence: Ac-VSETAA-cpY-AEIIDEEDT-
CONH2, C76H118N17O36P, Mass.: 1875.7, characterized before final
acetylation: C82H123N18O37P, Mass.: 1982.8 MS(ESI); 992.8 [MH2]
2
(100), 1003.3 [MHNa]2 (25).
Lifetime of pYFAK after Uncaging—A 25-ml sample of NBT-II cell
culture was centrifuged; the pellet was then treated with 250 l of 1%
Triton X-100 in phosphate-buffered saline solution and gently mixed
with a micropipette. The resulting mixture was transferred to a 1-ml
tube and centrifuged at high speed (13,000 rpm) for 8 min. An 80-l
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aliquot of the supernatant was added to 5.6 l of Rh-Ahx-pYFAK stock
solution (30.5 M) to give a final peptide concentration of 2 M. The
resulting mixture was incubated at 25 °C, and 3-l aliquots were taken
consecutively at 5, 10, 15, 20, and 25 min and diluted in 100 l of
phosphate-buffered saline, pH 7.5. Each sample was kept frozen at
78 °C until injected into the HPLC for analysis.
As a control, an 80-l aliquot of lysate was treated for 5 min with 400
M pervanadate to inactivate tyrosine phosphatases, and then 5.6 l of
stock Rh-Ahx-pYFAK solution was added to the lysate and the peptide
was incubated at room temperature. For analysis, 3-l aliquots were
taken at 10 and 20 min and added to 100 l of phosphate-buffered
saline, pH 7.5. Each sample was kept frozen at 78 °C until injection
onto the HPLC for analysis. 160 l of NBT-II cell lysate (from 20 ml of
culture) was incubated with Flu-pYFAK (final concentration 2 M).
GSTSrc SH2 and GSTPI3K C-terminal SH2 Expression and Puri-
fication—Src and PI3K SH2 domains were expressed and purified as
GST fusion proteins essentially following reported procedures (27). In
summary, plasmids encoding the GST fusion proteins were transformed
into bacteria Escherichia coli DH5-competent cells; Invitrogen). Bacte-
ria were grown to mid-log phase, induced at 37 °C for 3–4 h with
isopropyl-1-thio--D-galactopyranoside, and lysed by treatment with
lysozyme (1 mg/ml, 30 min) followed by sonication (phosphate-buffered
saline buffer, pH 7.4, with 100 mM EDTA, 1% Triton X-100, 10%
glycerol, 1 mM dithiothreitol, 0.1 mM 4-(2-aminoethyl)benzenesulfonyl
fluoride (AEBSF), 30 g/ml leupeptin, and 0.5 g/ml pepstatin A). The
lysates were clarified by centrifugation, and fusion proteins were puri-
fied by binding to glutathione-agarose beads (Amersham Biosciences).
Proteins were eluted from the beads (50 mM Tris-HCl, 10 mM reduced
glutathione, pH 8) and concentrated by centrifugation through a cellu-
lose membrane (10 kDa molecular mass cutoff; Millipore). Proteins
were quantified by Micro BCA protein assay kit (Pierce) relative to a
bovine serum albumin standard. All fusion proteins were analyzed by
Coomassie Blue staining and Western blot analysis with anti-GST
antibodies.
Kd Values for Peptide Binding to SH2 Domains of Src and PI3K—All
experiments were performed using a VP-ITC instrument from Microcal
Inc. Peptides and proteins were dialyzed extensively against the same
buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM -mercaptoethanol)
using a 500-Da molecular mass cutoff cellulose membrane (Spectrum
Laboratories Inc.). Initial experiments using lower pH resulted in pre-
cipitation of the protein and/or peptide during the titration.
In a typical titration, peptides (1–3 mM concentration) were added
over 25 injections (5 l) to purified GSTSH2 proteins (200–400 M)
that were present in the isothermal calorimeter cell at 25 °C. This
temperature was chosen to minimize the contributions of ligand-in-
duced refolding of the protein while maintaining a physiologically rel-
evant temperature of operation. In every titration the concentration of
the reactants was sufficient to result in saturation of the titration curve.
Biological Methods
Cell Culture—For the movement of NBT-II cells, suspension culture
Petri dishes (35 mm) were coated by incubating with 10 g/ml collagen
(rat tail type I) for 30 min. NBT-II cells (American Type Culture
Collection) were treated with trypsin and resuspended in Dulbecco’s
modified Eagle’s medium/F12 medium containing 10% fetal bovine
serum, plated at low density on the dishes, and cultured for 12 h
at 37 °C.
Competitive Binding Assay in Cell Lysates—As previously described,
chicken embryo cells were isolated from day 9 embryos and maintained
in Dulbecco’s modified Eagle’s medium  4% fetal bovine serum  1%
chick serum (28). FAK was expressed in chicken embryo cells using the
replication-competent, avian retroviral vector called RCAS, and cells
were transfected as previously described (28, 29). Cells were lysed in
modified radioimmune precipitation assay buffer (30) containing prote-
ase and phosphatase inhibitors as described (30). The protein concen-
tration of lysates was determined by using the bicinchonic acid assay
(Pierce). The expression of GST fusion proteins (Src or PI3K SH2
domains) was induced by using 0.1 mM isopropyl-1-thio--D-galactopy-
ranoside. E. coli were harvested, lysed by sonication, and the fusion
proteins purified by using glutathione-agarose beads (Sigma) as previ-
ously described (30).
GST pulldowns were performed from 0.2 mg of lysate from chicken
embryo cells expressing FAK. Lysates were precleared with 10 g of
GST. The supernatant was then incubated with 10 g of fusion protein
immobilized on glutathione-agarose beads either with or without pep-
tides at increasing concentrations for 1 h at 4 °C. The beads were
washed twice with lysis buffer and twice with phosphate-buffered sa-
line. Bound proteins were eluted by boiling in sample buffer (31) and
analyzed by Western blotting with polyclonal antiserum BC4 to recog-
nize FAK. Western blots were incubated with horseradish peroxidase-
conjugated secondary antibodies and processed for enhanced chemilu-
minescence (Amersham Biosciences).
Microinjection—Microinjection of peptides into cells was performed
with a semiautomatic Eppendorf InjectMan NI 2/Femtojet system.
Original Eppendorf Femtotip needles were loaded with 1.5–2 l of
injection solution. The base pressure of the system was adjusted (by
visual assessment of the fluorescent marker outflow from the microin-
jection needle in the 20–100 hectopascal range) to keep a constant low
outflow of the loaded solute into cell medium. Similarly, because of the
increasing viscosity of the loaded solution, the injection pressure was
adjusted to achieve a similar brightness of co-loaded fluorescent marker
in microinjected cells (50 to up to 1200 hectopascal in some cases). After
setting up the vertical limit position of the microneedle, each cell was
automatically injected with peptide solution by InjectMan with preset
speed of the microinjection needle movement. The velocity of the mi-
croneedle movement varied from 45 to 130 m/s. The procedure was
repeated to obtain the desired number of microinjected cells. Cells
microinjected with caged phosphopeptides were allowed to recover in
the tissue culture incubator for 30 min. During microinjection and
subsequent time lapse microscopy, cells were maintained at 37 °C and
CO2 was flushed over the dish. To distinguish between microinjected
and non-microinjected cells, a tracer (either rhodamine-labeled peptide
or rhodamine-dextran) was co-loaded with the peptides at a final con-
centration range 10% of that of biological test peptide.
We evaluated the consistency of microinjected volumes when differ-
ent caged peptides were introduced. NBT-II cells, seeded on glass or
plastic surface, were microinjected with either cpTyr397FAK or
Ala395cpTyr397FAK peptides together with fluorescent marker (rhoda-
mine dextran) as described above. Cells were left in the incubator for 1 h
and then placed in an environmental chamber on the microscope stage.
From phase contrast and epifluorescence images of cells loaded with
rhodamine dextran, the area of cells of interest was manually outlined
and the average value of fluorescence of the outlined area was deter-
mined using Metamorph imaging software routines. The mean value
(arbitrary units) of single cell average fluorescence was 105  27 for
cpTyr397FAK (269 cells) and 97  28 for Ala395cpTyr397FAK (143 cells).
The results indicated that constant volumes of the solutions containing
cpTyr397FAK or Ala395cpTyr397FAK peptides could be microinjected.
Photoactivation—For uncaging of caged FAK phosphopeptides, UV
light from an Argon ion laser (Spectra Physics), with multiline optics
covering a 333.6–363.8-nm range, was focused onto a 8-m-diameter
spot on the specimen using a 20 Nikon objective. For all experiments,
the estimated power of the laser beam after passing through the objec-
tive was 67 microwatts (measured by a power meter) and the duration
of illumination was 100 ms.
Concentration Estimates of Microinjected and Uncaged Peptide—
Estimates for the concentration of the microinjected peptides as well as
uncaged peptide are given in Table I. Using the Eppendorf Injectman,
we estimate that 20–200 fl of peptide is microinjected into each cell. If
the average cell volume of NBT-II cells is 1.5 pl, an additional 1–10%
(32) of the total cell volume is added by microinjection. To estimate the
concentrations of peptide after uncaging, a quantum efficiency of un-
caging for these peptides of 0.3 was used based on characterization of a
paxillin peptide with the same caging moiety (33).
Microscopy and Cell Motility Measurements—Cell migration was
measured with a Nikon Diaphot 300 microscope using 20 Phase 3 DL
0.75 N.A. objective. The microscope was equipped with a Cooke Sensi-
cam QE CCD camera and a semiclosed perfusion microincubator (Har-
vard Apparatus). The temperature of the chamber was kept at 37 °C,
and CO2 flow was maintained over the Petri dish. Time lapse images of
migrating cells were taken between 1–4 h; images were recorded every
5 min. The movement of individual cells was analyzed with Metamorph
software (Universal Imaging).
RESULTS
Characterization of Peptide Properties
Peptides Employed—The series of peptides synthesized for
this study is shown in Fig. 1, and the rationale for their design
is given under “Discussion.” The peptides are based on the
sequence of FAK from residues Val391 to Thr406 surrounding
the autophosphorylation site at Tyr397 (VSETDD-
pY397AEIIDEEDT) (pTyr397FAK); a closely related peptide
(VSETDDY397AEIIDEED) has been previously used in studies
to inhibit Src SH3-SH2/phosphoprotein interactions in a com-
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petition enzyme-linked immunosorbent assay (34). For photo-
activation, a caged phosphotyrosine (cpY, or cpTyr) was intro-
duced into the sequence (VSETDDcpY397AEIIDEEDT) designated
cpTyr397FAK. In addition, a similar caged phosphotyrosine peptide
with an amino acid substitution at position 395 (alanine for aspar-
tic acid) was synthesized (VSETADcpY397AEIIDEEDT) and desig-
nated Ala395cpTyr397FAK. A caged phosphotyrosine-containing
peptide with 2 amino acid substitutions (D395/396A) (VSET-
TABLE I
Estimated concentration of microinjected and uncaged peptide
Peptide Concentration of peptidein microinjection needle





pTyr397FAK 977 M 10–100 NAc
195 M 2–20 NAc
98 M 1–10 NAc
cpTyr397FAK 930 M 9–90 2.7–27
Ala395cpTyr397FAK 1.394 mM 14–140 4–40
Ala395pTyr397FAK 3.17 mM 32–320 NAc
370 M 3–30 NAc
Ala395Ala396cpTyr397FAK 1.232 mM 12–120 3.6–36
Partially scrambled FAK 513 M 5–50 NAc
a The amount microinjected is based on microinjecting 1–10% of total cell volume (28) and an estimated NBT cell volume of 1.5 pl.
b The lower limit estimate of uncaged peptide is based on the quantum efficiency of peptide uncaging (0.3 in vitro) (29) and complete uncaging
in a cylindrical volume 9 m in diameter and 4 m high during the 100-ms irradiation time. Some diffusion of caged peptide into the irradiation
zone during the irradiation will increase the amount of peptide uncaged.
c NA, not applicable.
FIG. 1. Peptides employed in this
study. See “Results” for description.
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AAcpY397AEIIDEEDT), designated Ala395Ala396cpTyr397FAK, and
another non-caged peptide with amino acid sequence N-terminal of
the phosphotyrosine shuffled (AcDDVTESpY397AEIIDEEDT), des-
ignated partially scrambled pYFAK, were also synthesized.
Kd Values for Peptide Binding to SH2 Domains of Src and
PI3K—As likely targets for peptide binding are Src and PI3K,
we determined the binding affinities of several of the phos-
phopeptides to GST fusions of Src and PI3K SH2 domains
using isothermal titration calorimetry (Table II). Dissociation
constants for pTyr397FAK, Ala395pTyr397FAK, and partially
scrambled pTyr FAK binding to Src SH2 domains are similar at
about 4 M. Current models for binding of similar peptides to
Src SH2 motifs place emphasis on the pYAEI sequence C-
terminal to Tyr397 in FAK as the major determinant of binding.
In addition, all peptides tested bind more strongly to Src as
compared with PI3K SH2 motifs with Kds that are about one
order of magnitude lower.
Competitive Binding Assay in Cell Lysates—The results in
Fig. 2 show that in cell lysates, pTyr397FAK is able to compete
for FAK binding to the Src SH2 domain in the M range.
Surprisingly, the Ala395pTyr397FAK peptide competes even
more effectively for FAK binding to the Src SH2 domain. Both
peptides compete for FAK-PI3K binding in the 10–50-M
range, and the Ala395pTyr397FAK competes better than the
wild type peptide. The lysate competition assay results and the
isothermal calorimetry determination of Kds of various peptide
bindings to purified SH2 domains from PI3K and Src are qual-
itatively consistent. However, the data from these two meas-
urements show the Ala395pTyr397FAK peptide is not defective
for binding to PI3K, contrary to predictions based on literature
precedent (35).
Lifetime of pTyr397FAK in Cell Lysates after Uncaging—
After microinjection of the pTyr397FAK peptide or uncaging of
the cpTyr397FAK peptide, the most likely mode of degradation
is via dephosphorylation by endogenous phosphatases. Because
this action would deactivate the peptide reagent, it was impor-
tant to estimate the kinetics of dephosphorylation of the intact
phosphopeptide. Using HPLC analysis, the dephosphorylation
of the FAK phosphopeptides in NBT-II cell lysates was followed
at 25 °C (Fig. 3). Aliquots of NBT-II cell lysates incubated with
Rh-pTyr397FAK peptide were taken every 5 min and analyzed
by HPLC using rhodamine fluorescence for monitoring. We
observed the formation of a new product with retention time
that matches that of the Rh-Tyr397FAK sample (Fig. 3A). The
resulting chromatograms show a steady decrease in the peak
corresponding to the phosphopeptide and a simultaneous in-
crease in the intensity of another fluorescent peak with the
same retention time as the unphosphorylated peptide. From
the HPLC traces, we conclude that the half-life of the phos-
phopeptide in the NBT-II cell lysates is 10–15 min, in agree-
ment with reported literature values (34). As expected, incuba-
tion of the peptide with pervanadate-treated cell lysates does
not show degradation of the peptide during the time of the
experiment, suggesting that the change in retention time of the
peptide was due to dephosphorylation by tyrosine phospha-
tases in the lysate (Fig. 3B). Over a similar time frame, the
caging group protects the phosphate group from phosphatase-
mediated degradation (see Fig. 3C).
Effects of Peptides on Cell Migration
Uncaging of FAK 397 Phosphopeptides Produces a Transient
Arrest of Lamellar Extension—NBT-II cells were microinjected
with caged phosphopeptides and a tracer (see “Materials and
Methods”) and then allowed to recover in a 37 °C incubator
with 5% CO2 for 30 min. After recovery, microinjected cells
were tracked to ensure there were no migration differences
attributable to microinjection. The phosphopeptides were un-
caged by two brief flashes of UV laser light (one directed at the
lamella and the second on the main cell body (see blue circles
representing the irradiation spots in Fig. 4B; spots drawn to
scale). Typical results are given in Fig. 4. The top panel (Fig.
4A) shows that migration is normal after cells have recovered
from microinjection of cpTyr397FAK. After uncaging, the la-
mella of the photoactivated NBT-II cells ceased to extend for
20–40 min (Fig. 4B, red line). During this time, there was little
or no change in the morphology of the lamellipodium, suggest-
ing a temporary increase in adherence to the substrate. The
lamella stopped protruding within the first minute after pho-
toactivation. Note, however, that the trailing edge of the cell
continued to move forward (green line indicates the initial
position of cell body). In Fig. 4C, non-loaded cells were also
irradiated to serve as controls for nonspecific photodamage.
Under these conditions, these cells continued to migrate at the
same rate as before irradiation.
Distribution of lamellar arrest duration in different cells is
given in Fig. 5A. In these experiments, 18 of 25 cells displayed
transient lamellar arrest after photoactivation of cpTyr397FAK
(2 cells showed no effect; 4 cells were difficult to assess; 1 cell
slowed but did not stop) (Fig. 5A). Two laser shots were re-
quired to achieve the effect, including one over the perinuclear
region. A single irradiation focus on the lamellipod was insuf-
ficient. This suggests that this migration “phenotype” is a glo-
bal effect in the sense that sufficient free phosphopeptide must
be released for an effect, and this is provided by the larger
volume of uncaging when the beam is directed over the perinu-
clear zone as opposed to positioning the beam over the much
thinner lamella area.
Uncaging Other Peptides—The Ala395cpTyr397FAK peptide
(Fig. 1) contains an amino acid substitution in position 395 of
the FAK sequence (D395A) that causes full-length FAK mu-
tants to bind to Src but not to PI3K (35). NBT-II cells were
microinjected following the procedure used for the caged
pTyr397FAK peptides. When the Ala395cpTyr397FAK was un-
caged, little lamellar arrest was seen (Fig. 5B). Of 20 cells, 14
showed no lamellipodial arrest, 4 temporarily ceased protru-
sion (2 cells for 15 min, 1 cell for 10 min, and 1 cell for 5 min),
TABLE II
Dissociation constants for peptide binding to GSTSH2 motifs of Src
and N-terminal p85 of PI3K





pTyr397FAK 3.7  1.5 47  12
Ala395pTyr397FAK 4.7  0.8 54  13
Partially scrambled pyFAK 3.5  1.6 46  18
FIG. 2. Ability of phosphorylated FAK peptides to compete for
binding to Src and PI3K SH2 domains. The Src and PI3K SH2
domains were expressed as GST fusion proteins and immobilized to
glutathione-agarose beads. FAK-expressing chicken embryo cell lysate
was precleared by incubation with GST alone immobilized to glutathi-
one-agarose beads. The cleared lysates were then incubated with GST
(lane 2), GSTSrc SH2 (lanes 3–9), or GSTPI3K SH2 (lanes 10–16).
Pulldowns were also performed in the presence of the wild type
pTyr397FAK peptide or the Ala395pTyr397FAK peptide at concentrations
of 2 M (lanes 4, 7, 11, 14), 5 M (lanes 5, 8, 12, 15), or 45 M (lanes 6,
9, 13, 16). The beads were washed, and bound FAK was detected by
Western blotting. 25 g of lysate was run as a control (lane 1).
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FIG. 3. A, HPLC traces of Rh-Ahx-
pTyr397FAK (Ahx; 6-aminohexanoic acid
linker) incubated with NBT-II cell lysate
at 5, 10, 15, 20, and 25 min showing the
increase of unphosphorylated peptide. B,
superposition of the HPLC traces of the
stock of Rh-Ahx-pTyr397FAK and the pep-
tide after 20 min of incubation with pervana-
date-treated cell lysate, showing that the
peptide is stable. C, stability of caged phos-
phopeptide (Rh-Ahx-cpTyr397FAK) in cell
lysates.
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and 2 cells were difficult to classify. However, when
Ala395pTyr397FAK was directly introduced by microinjection,
producing a significantly higher concentration of phosphoty-
rosine peptide, transient lamellar arrest did occur (see
below).
A caged FAK phosphotyrosine peptide containing 2 amino
acid substitutions in positions 395 and 396 of the FAK se-
quence (Ala395Ala396cpTyr397FAK) was designed as a control
peptide for uncaging based on the fact that full-length FAK
mutants containing the same substitutions have much reduced
binding to Src and PI3K (35). Upon photoactivation, most mi-
croinjected cells exhibited no appreciable changes in migration
speed (results summarized in Fig. 5C). These experiments
demonstrate the specificity of the peptide sequence required to
halt cell protrusion and eliminate the possibility that the ef-
fects of uncaging cpTyr397FAK are due to the nitrosoacetophe-
none side product liberated by photoactivation.
Microinjection of pY397FAK Phosphopeptides Also Produces
Transient Lamellar Arrest—Corroborating the contention that
uncaging within the lamella cannot release sufficient peptide
for an effect is the experiment that directly microinjecting
pTyr397FAK peptide produces a similar phenotype (Fig. 6). The
pTyr397FAK-loaded NBT-II cell exhibits a temporary inhibition
of protrusion before starting to extend small local protrusions
between 20–30 min after microinjection and then resumes
migration at 45 min. Intermediate concentrations (5–10-fold
dilution; 200 M in the needle) of pTyr397FAK peptide were
required to produce the same effect as uncaging cpTyr397FAK.
Microinjection of undiluted pTyr397FAK peptide (1 mM in the
needle) stops migration, and the cells do not recover for the
duration of the experiment (1–2 h). This experiment also indi-
cates that the lamellar arrest phenotype is due to the phospho-
tyrosine peptide itself and not the side product produced after
liberation of the caging group. In the pTyr397FAK experiments,
described in Fig. 6, changes in the migration rate could be
because of either microinjection or peptide. These two possibil-
ities were distinguished by cell morphology. NBT-II cells that
have been damaged by microinjection no longer exhibited the
fan-like lamellar morphology of a normally migrating cell. In-
stead, they became rounded and eventually collapsed. In Fig. 6,
the microinjected cell maintained its leading lamella and mi-
gration resumed after 45 min, indicating that the altered mi-
gration was because of the phosphotyrosine peptide and not the
microinjection itself.
Caged and free Ala395pTyr397FAK (Fig. 1) were also micro-
injected into migrating NBT-II cells. Although photoactivation
of the caged version of this peptide did not alter migration (Fig.
4B), direct microinjection of Ala395pTyr397FAK caused tempo-
rary lamellar arrest in 10 of 14 cells (3 cells changed direction,
1 cell showed no arrest). However, microinjection of the par-
tially scrambled FAK phosphopeptide (Fig. 1) did not alter cell
migration significantly (9 cells exhibited no noticeable changes,
4 cells changed direction but continued migrating). A summary
of the peptide effects on cell migration together with their
binding constants to Src and PI3K SH2 motifs and estimated
intracellular concentrations is given in Table III.
DISCUSSION
Design of Caged Phosphotyrosine Peptides—Phosphotyrosine
peptides containing the amino acids surrounding and including
pTyr397FAK have been used previously to study SH2 binding
domains of PI3K and Src (11, 17, 34, 36–38). This region of
FAK is known to interact not only with the SH2 domains of Src
and PI3K but also with SH2 motifs in phospholipase C-, SHC,
Nck2, and Grb7 (10, 12, 15, 16). Chen et al. (11) utilized a
12-amino acid phosphotyrosine peptide to disrupt FAK binding
to PI3K (GST-tagged p85 N-terminal SH2 domain) (Kd  10
M) and to Src (GST-tagged Src-SH2) (Kd  3 M). These
experiments showed that binding of the phosphotyrosine pep-
tide to the p85 subunit of PI3K increased PI3K activity in cell
lysates. Other studies also demonstrated the ability of similar
phosphotyrosine peptides derived from FAK to activate c-Src
(17) and PI3K (39–42). Phosphopeptides that bind Src-SH2
with higher affinity than the Src autoregulatory sequence in-
duce the open, active conformation of the enzyme. Similarly,
binding of phosphopeptide to the SH2 domain of p85 (regula-
tory) subunit of PI3K releases the auto-inhibitory effect per-
mitting catalytic activity of p110 subunit. All of these studies
FIG. 4. Uncaging of cpTyr397FAK
peptide produces transient lamellar
arrest. The red line indicates the initial
position of the leading edge, the green ref-
erence line indicates the initial position of
the trailing edge, and the blue circles in-
dicate the regions of irradiation (to scale).
A, the top panel shows a single migrating
cell loaded with cpTyr397FAK before laser
irradiation. B, after photoactivation in
spots shown in circles (see “Materials and
Methods” for details), the release of the
phosphopeptide temporarily halts lamel-
lipodial protrusion for 25 min, after which
migration resumes. The posterior cell
body continues to move forward after pep-
tide photorelease (see green reference
line), and the lamellipodium broadens be-
fore migration continues. C, the bottom
panel depicts a non-loaded, irradiation
control showing normal migration after
two 100-ms laser irradiations in the spots
shown.
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FIG. 5. Distribution of lamellar ar-
rest durations produced by uncaging
cpTyr397FAK (A), Ala395cpTyr397FAK
(B), and Ala395Ala396cpTyr397FAK (C).
FIG. 6. NBT-II cells after microinjection with pTyr397FAK peptide. The time points refer to time elapsed after microinjection. The red line
indicates the initial position of the leading lamellar edge. The cell stops protruding after microinjection. Between 20–30 min, the cell begins to form
two small extensions at different regions of the cell. By 45 min, the cell recovers, shows broad lamellipodial extension, and resumes migration.
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suggest that the phosphotyrosine peptides such as
pYTyr397FAK and cpTyr397FAK could be used as probes inside
living cells.
Besides the pYTyr397FAK and cpTyr397FAK peptides, addi-
tional phosphotyrosine peptides and their caged counterparts
were synthesized as probes and controls (Fig. 1) based on the
following rationale. A full-length FAK mutant containing the
D395A substitution (2 amino acids upstream from the phospho-
tyrosine) binds Src, but not PI3K (35). Further, analysis of the
consensus PI3K SH2 domain binding motif and structural stud-
ies support the role of residues N-terminal to the phosphoty-
rosine in PI3K binding (37, 38). Therefore, peptides with altered
sequences upstream of the phosphotyrosine were designed.
These include the Ala395cpTyr397FAK peptide, mimicking the
D395A FAK mutant (35), the Ala395Ala396cpTyr397FAK peptide,
which contains two substitutions that disrupt the interaction
between FAK and both Src and PI3K (35), and a partially scram-
bled FAK phosphotyrosine peptide with amino acids N-terminal
to the phosphotyrosine scrambled (corresponding to FAK 391–
396). While these peptides were designed to test the in vivo role
of amino acids N-terminal to the phosphotyrosine and to distin-
guish between interactions with Src and PI3K, the isothermal
titration calorimetry and lysate competition assays show that the
Ala395pTyr397FAK peptide binds to both the Src and PI3K SH2
domains. Thus, different results were obtained with the synthetic
mutant peptides and mutants of the full-length protein (35),
presumably reflecting additional features of full-length FAK, Src,
and/or PI3K that contribute to the stability of the interaction.
Although the peptides could not discriminate between effects
upon Src and PI3K in vivo, the results do demonstrate that
sequences N-terminal to the phosphorylated tyrosine play an
important role in the observed biological responses.
Selected peptides were caged at the key phosphotyrosine
residue using recently developed methodology (25). 1-(2-
Nitrophenyl)ethyl (NPE) was chosen as the caging group
because it satisfies key requirements of biologically useful
caging groups and those of Fmoc-based solid phase peptide
synthesis (19, 33). The NPE can be photochemically released
with reasonable quantum efficiency at wavelengths around
350 nm (33, 43), and the photo-byproduct, nitrosoacetophe-
none, is less harmful to cells than the corresponding aldehyde
released by photolysis of commonly implemented o-nitroben-
zyl caging groups (25).
Properties of the Uncaged Peptides—The phosphorylated
peptides have a half-life in cell lysates of 10–15 min, roughly
consistent with lamellar arrest times. This half-life is only an
estimate of stability in intact cells. Isothermal calorimetry
studies determining the affinities for the phosphorylated pep-
tides binding to the SH2 domains of Src and PI3K differ by
about an order of magnitude, with binding to Src being tighter.
These values approximate those reported previously, and any
differences in the values probably arise from slight differences
in peptide sequences and different methods used to determine
affinities (44). Results from the lysate competitive binding as-
says (Fig. 2) were qualitatively consistent with the isothermal
calorimetry data.
Mechanism of Action of the pYFAK Peptides—These phos-
photyrosine peptides intervene in signal transduction-medi-
ated events downstream of FAK by abruptly increasing the
concentration of pTyr397FAK either upon photoactivation or
microinjection to produce transient lamellar arrest. Indeed,
this phenotype is remarkably similar to that seen when ker-
atocytes are treated with function-blocking anti-1 integrin
antibodies (45), suggesting that the uncaged peptide intervenes
in integrin-mediated signaling pathways. For photoactivation,
it appears that in order to liberate sufficient phosphopeptide
for an effect, irradiation of the thicker part of the cell was
required. Free phosphopeptide then presumably diffuses rap-
idly throughout the cell and binds to the cognate targets. This
view was corroborated by the observation that direct microin-
jection of intermediate concentrations of phosphopeptides pro-
duced a similar transient lamellar arrest phenotype (Fig. 6).
Thus, in this case, although temporally defined effects were
produced, localized effects could not be created by photoactiva-
tion. A similar effect was observed by Walker et al. (21) who
demonstrated that local photorelease of caged peptide inhibi-
tors of calmodulin or myosin light chain kinase did not produce
arrest of eosinophil migration, but global release over the en-
tire cell (similar to microinjection) did. On the other hand, local
photorelease of caged actin-binding proteins did produce dra-
matic local perturbations in migration (22, 24) presumably
because a sufficient number of released proteins quickly found
their abundant G- or F-actin targets via diffusional encounters.
Two of the most widely studied FAK-binding proteins are Src
and PI3K, and previous work has indicated the importance of
these two proteins for migration in many cell types (46–49).
Our binding and competitive inhibition studies indicate that
uncaged peptide could bind to both of these FAK effectors. The
literature cited above indicates that similar peptides can acti-
vate both Src and PI3K. Thus, temporally and spatially inap-
propriate activation produces lamellar arrest until the phos-
phopeptide loses activity via dephosphorylation, at which time
normal migration resumes. This does not appear to be the
whole story, however. Comparing the actual uncaging results
TABLE III













Effect on cell migration
Src PI3K
M
VSETDDcpYAEIIDEEDT (cpTyr397FAK) 9–90 2.7–27 Temporarily halts lamellar protrusion
VSETDDpYAEIIDEEDT (pTyr397FAK)
(microinjection only)
3.7 47 2–20 NAc Temporarily halts lamellar protrusion
VSETADcpYAEIIDEEDT (Ala395cpTyr397FAK) 14–140 4–40 No effect on migration
VSETADpYAEIIDEEDT (Ala395pTyr397FAK)
(microinjection only)
4.7 54 3–30 NAc Temporarily halts lamellar protrusion
VSETAAcpYAEIIDEEDT
(Ala395Ala396cpTyr397FAK)
NDd NDd 12–120 3.6–36 Does not affect migration
DDVTESpYAEIIDEEDT (partially scrambled
FAK) (microinjection only)
3.5 46 5–50 NAc No effect on migration
a From Table II.
b From Table I.
c NA, not applicable.
d ND, not determined.
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from cells with the lysate competition results suggests that
other FAK effectors such as Shc, PLC-, Grb7, or Nck2 may
also play a role. Although uncaging of cpTyr397FAK produced
the lamellar arrest phenotype, uncaging of Ala395cpTyr397FAK did
not; however, the direct microinjection of Ala395pTyr397FAK did
produce arrest. This suggests that at the higher microinjected con-
centrations, Ala395pTyr397FAK most likely titrates other impor-
tant FAK-effector interactions that are available to uncaged
cpTyr397FAK. Further downstream effects that produce this dis-
tinctive phenotype remain to be elucidated. These could include 1)
an increase in lamellum adhesion or 2) the abrogation of lamellar
protrusion by indirectly inhibiting Rac and/or Rho (50–54).
Advantages of Photoactivation of Phosphopeptides in Cell
Biology—Chemical probes, including peptides and proteins
that can be activated at will, are powerful tools to study signal
transduction in dynamic processes like cell migration. Caged
phosphotyrosine peptides are examples of such probes, as they
can be introduced into cells in an inactive form and subse-
quently activated by UV light, producing a temporally and, in
some cases, spatially controlled biological response. Utilization
of caged phosphopeptides provides several technical advan-
tages in in situ studies of signal transduction. The caged group
attached directly to the phosphotyrosine increases the stability
of the peptide by protecting it from endogenous protein tyrosine
phosphatases. Additionally, the phosphopeptide remains in an
“inactive” state until the photoactivation step, allowing precise
timing of the perturbation. Because the caged phosphopeptides
are inactive, each cell can serve as its own control for
microinjection.
Nevertheless, challenges remain. It is clear from these stud-
ies that the use of short caged phosphopeptides as cellular
probes may introduce ambiguity into the studies, because the
limited binding determinants of the peptides may not faithfully
reflect the behavior of the intact proteins upon which they are
patterned. Thus, recent emphasis has been placed on the de-
velopment of a general methodology for the incorporation of
caged phosphoamino acids into native proteins via the suppres-
sor tRNA methodology (55); in the future, this should expand
the scope of the caged phosphoprotein-based strategies for
probing signal transduction events in cell migration. An addi-
tional interpretational limitation is the determination of the
absolute amount of peptide microinjected. This measurement is
also important for quantitative modeling studies. However, the
absolute amount of peptide loaded is difficult to measure di-
rectly because there are no convenient assays apart from the
actual bioassay consisting of a changed migratory phenotype.
In the future, we will concentrate on characterizing peptides
conjugated to a fluorophore or caged fluorophore. The fluores-
cent signal from such peptides could be used directly in single
cell concentration assays or in single cell fluorescence correla-
tion spectroscopy measurements to determine concentration.
Such efforts are extremely important, but they will involve
characterization of essentially new peptides with different sol-
ubility, binding, and photochemical properties. Our studies
show that defined intervention by the photoactivation method-
ology in signal transduction networks is an attractive method
to test various hypotheses. However, to make the mechanistic
connection between a given phenotype and the signaling net-
work involved, more knowledge of relative functional signifi-
cance of pathways downstream of the uncaging intervention
will be required.
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